uniQure N.V.

NASDAQ:QURE  
19.16
+0.52 (+2.79%)
Products

uniQure Says FDA Accepts BLA For Etranacogene Dezaparvovec Under Priority Review

Published: 05/24/2022 12:21 GMT
uniQure N.V. (QURE) - Uniqure Announces FDA Acceptance of Biologics License Application for Etranacogene Dezaparvovec Under Priority Review.